Literature DB >> 29383660

Economic Burden of Clostridium difficile Infection in European Countries.

Elena Reigadas Ramírez1,2,3, Emilio Santiago Bouza4,5,6,7.   

Abstract

Clostridium difficile infection (CDI) remains a considerable challenge to health care systems worldwide. Although CDI represents a significant burden on healthcare systems in Europe, few studies have attempted to estimate the consumption of resources associated with CDI in Europe. The reported extra costs attributable to CDI vary widely according to the definitions, design, and methodologies used, making comparisons difficult to perform. In this chapter, the economic burden of healthcare facility-associated CDI in Europe will be assessed, as will other less explored areas such as the economic burden of recurrent CDI, community-acquired CDI, pediatric CDI, and CDI in outbreaks.

Entities:  

Keywords:  C. difficile infection; Economic burden; Economic costs; Europe; Length of stay

Mesh:

Year:  2018        PMID: 29383660     DOI: 10.1007/978-3-319-72799-8_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.

Authors:  C M Thorpe; L A McDermott; M K Tran; J Chang; S G Jenkins; E J C Goldstein; R Patel; B A Forbes; S Johnson; D N Gerding; D R Snydman
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

2.  Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.

Authors:  Deiziane V S Costa; Natalie V S Pham; Rachel A Hays; David T Bolick; Sophia M Goldbeck; Melinda D Poulter; Sook C Hoang; Jae H Shin; Martin Wu; Cirle A Warren
Journal:  Antimicrob Agents Chemother       Date:  2022-07-21       Impact factor: 5.938

3.  Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.

Authors:  Miguel Salavert; Javier Cobo; Álvaro Pascual; Belén Aragón; Stefano Maratia; Yiling Jiang; Susana Aceituno; Santiago Grau
Journal:  Adv Ther       Date:  2018-10-16       Impact factor: 3.845

4.  Clostridioides difficile Activates Human Mucosal-Associated Invariant T Cells.

Authors:  Isabel Bernal; Julia Danielle Hofmann; Björn Bulitta; Frank Klawonn; Annika-Marisa Michel; Dieter Jahn; Meina Neumann-Schaal; Dunja Bruder; Lothar Jänsch
Journal:  Front Microbiol       Date:  2018-10-25       Impact factor: 5.640

5.  In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation.

Authors:  Breanna McSweeney; Jessica R Allegretti; Monika Fischer; Huiping Xu; Karen J Goodman; Tanya Monaghan; Carmen McLeod; Benjamin H Mullish; Elaine O Petrof; Emmalee L Phelps; Roxana Chis; Abby Edmison; Angela Juby; Ralph Ennis-Davis; Brandi Roach; Karen Wong; Dina Kao
Journal:  Gut Microbes       Date:  2019-05-23

6.  A Novel Bacteriophage Lysin-Human Defensin Fusion Protein Is Effective in Treatment of Clostridioides difficile Infection in Mice.

Authors:  Zhong Peng; Shaohui Wang; Mussie Gide; Duolong Zhu; Hiran Malinda Lamabadu Warnakulasuriya Patabendige; Chunhui Li; Jianfeng Cai; Xingmin Sun
Journal:  Front Microbiol       Date:  2019-01-11       Impact factor: 5.640

7.  The engulfasome in C. difficile: Variations on protein machineries.

Authors:  Abigail Kelly; Paula S Salgado
Journal:  Anaerobe       Date:  2019-08-27       Impact factor: 3.331

8.  Clinical impact of a Clostridioides (Clostridium) difficile bedside infectious disease stewardship intervention.

Authors:  María Olmedo; Maricela Valerio; Elena Reigadas; Mercedes Marín; Luis Alcalá; Patricia Muñoz; Emilio Bouza
Journal:  JAC Antimicrob Resist       Date:  2020-08-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.